Evotec SE ADR (EVO)

Currency in USD
3.75
-0.13(-3.35%)
Closed·
After Hours
3.71-0.04(-1.07%)
·
EVO Scorecard
Full Analysis
High shareholder yield
EVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.753.82
52 wk Range
2.845.64
Key Statistics
Prev. Close
3.88
Open
3.82
Day's Range
3.75-3.82
52 wk Range
2.84-5.64
Volume
64.31K
Average Volume (3m)
121.59K
1-Year Change
-2.08%
Book Value / Share
5.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EVO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.05
Upside
+61.21%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Evotec SE ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Evotec SE ADR Company Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Compare EVO to Peers and Sector

Metrics to compare
EVO
Peers
Sector
Relationship
P/E Ratio
−5.6x12.4x−0.5x
PEG Ratio
0.040.360.00
Price/Book
1.3x2.8x2.6x
Price / LTM Sales
1.5x5.0x3.3x
Upside (Analyst Target)
81.6%423.8%43.5%
Fair Value Upside
Unlock30.3%6.9%Unlock

Analyst Ratings

4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.05
(+61.21% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-0.1021 / -0.0107
Revenue / Forecast
226.83M / 249.56M
EPS Revisions
Last 90 days

EVO Income Statement

People Also Watch

14.34
OSCR
+3.76%
25.21
CNC
-2.63%
20.230
ZETA
+27.47%
51.790
ASTS
-1.48%
67.51
MP
-1.29%

FAQ

What Stock Exchange Does Evotec SE ADR Trade On?

Evotec SE ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Evotec SE ADR?

The stock symbol for Evotec SE ADR is "EVO."

What Is the Evotec SE ADR Market Cap?

As of today, Evotec SE ADR market cap is 1.35B.

What Is Evotec SE ADR's Earnings Per Share (TTM)?

The Evotec SE ADR EPS (TTM) is -1.17.

When Is the Next Evotec SE ADR Earnings Date?

Evotec SE ADR will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is EVO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Evotec SE ADR Stock Split?

Evotec SE ADR has split 1 times.

How Many Employees Does Evotec SE ADR Have?

Evotec SE ADR has 4766 employees.

What is the current trading status of Evotec SE ADR (EVO)?

As of 07 Aug 2025, Evotec SE ADR (EVO) is trading at a price of 3.75, with a previous close of 3.88. The stock has fluctuated within a day range of 3.75 to 3.82, while its 52-week range spans from 2.84 to 5.64.

What Is Evotec SE ADR (EVO) Price Target According to Analysts?

The average 12-month price target for Evotec SE ADR is USD6.04524254, with a high estimate of USD8.21944963 and a low estimate of USD3.10750933. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +61.21% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.